Omeros Corporation Reports Second Quarter 2018 Financial Results

Go back to Omeros Corporation Reports Second Quarter 2018 Financial Results

Omeros Corp. (OMER) PT Raised to $32 at Maxim Group

August 10, 2018 7:50 AM EDT

Maxim Group raised its price target on Omeros Corp. (NASDAQ: OMER) to $32.00 (from $25.00) while maintaining a Buy rating.

Analsyt Jason McCarthy notes valuation has risen significantly since the end of 1Q18 with resolution of the pass-through status for Omidria, which should... More

Omeros (OMER) Misses Q2 EPS by 1c

August 9, 2018 4:44 PM EDT

Omeros (NASDAQ: OMER) reported Q2 EPS of ($0.70), $0.01 worse than the analyst estimate of ($0.69).

During the last quarter, we made significant strides across multiple fronts, said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. For OMS721, our MASP-2 inhibitor, Phase 3... More